Kimbell Duncan

Board Member at Curemark

Mr. Duncan is an investment professional with over 30 years’ experience in trading, principal transactions and early-stage venture investing. He began his career as a trader at Goldman Sachs in 1987, moving to Nomura, Credit Suisse and Mizuho, leading teams conducting principal investment activities. He has been an active angel investor since 2006, focusing on equity investments in promising, early-stage biotechnology companies, including Infirst Healthcare Limited, Pharmajet Ltd, Peptcell Limited and Curemark LLC. He sits on the board of each of his portfolio companies. He co-founded Rush Foundation in 2010, a charity focused on funding innovative solutions in the fight against the HIV pandemic in sub-Saharan Africa. Kim holds a BS in Electrical and Electronics Engineering from Yale University, a MS in Biotechnology from Georgetown University and is currently a candidate for PhD in Pharmacology and Physiology from Georgetown University.

Links


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Curemark

Curemark is a socially driven biotechnology company that focuses on the treatment of autism and other neurological diseases.


Headquarters

Rye, United States

Employees

11-50

Links